Evaxion A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
3.120
-0.100 (-3.11%)
Mar 9, 2026, 3:21 PM EDT - Market open
Evaxion Revenue
In the year 2025, Evaxion had annual revenue of $7.53M with 125.12% growth.
Revenue (ttm)
$7.53M
Revenue Growth
+125.12%
P/S Ratio
3.57
Revenue / Employee
$163,652
Employees
46
Market Cap
26.02M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kyntra Bio | 8.30M |
| Cue Biopharma | 7.10M |
| Dyadic International | 3.34M |
| IGC Pharma | 1.11M |
| Exicure | 500.00K |
| Hyperion DeFi | 345.32K |
EVAX News
- 2 days ago - Evaxion A/S (EVAX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Evaxion announces business update and full year 2025 financial results - GlobeNewsWire
- 4 days ago - Evaxion plans to file 2025 annual report later today - GlobeNewsWire
- 7 days ago - Evaxion to announce business update and full year 2025 financial results on March 5, 2026 - GlobeNewsWire
- 7 weeks ago - Evaxion expands AI-Immunology™ platform into autoimmune diseases - GlobeNewsWire
- 2 months ago - Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week - GlobeNewsWire
- 2 months ago - Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out - Benzinga
- 2 months ago - Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2 - GlobeNewsWire